NCT03820414 is a Phase 1 clinical trial of CRV 101 in Herpes Zoster, sponsored by Curevo Inc.

Who is sponsoring NCT03820414?

NCT03820414 is sponsored by Curevo Inc.

What drugs are being tested in NCT03820414?

Interventions in NCT03820414: CRV 101, Placebo.

What condition does NCT03820414 study?

NCT03820414 studies Herpes Zoster, Varicella Zoster.

Is NCT03820414 still recruiting?

NCT03820414 is currently completed. Last updated 11 February 2021.

Last reviewed 2021-02-11 · How we verify

NCT03820414

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects

Completed Phase 1 Last updated 11 February 2021

What this trial tests

Phase 1 trial testing CRV 101 in Herpes Zoster in 90 participants. Completed in 30 April 2020.

Timeline

3 January 2019

Primary endpoint
4 April 2020

30 April 2020

Quick facts

Lead sponsor	Curevo Inc
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	quadruple
Primary purpose	prevention
Enrollment	90
Start date	3 January 2019
Primary completion	4 April 2020
Estimated completion	30 April 2020
Sites	1 location across United States

Drugs / interventions tested

CRV 101 — full drug profile →
Placebo

Conditions studied

Herpes Zoster — all drugs for Herpes Zoster →
Varicella Zoster — all drugs for Varicella Zoster →

Sponsor

Curevo Inc — full company profile →

Who can join

Adults 18 to 49, any sex, with Herpes Zoster or Varicella Zoster. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this clinical trial is to evaluate the safety, tolerability, and immunogenicity of vaccine candidate CRV-101, investigational vaccine in healthy adult subjects in the United States.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Herpes Zoster Vaccines.
Harbecke R, Cohen JI, Oxman MN. · · 2021 · cited 127× · PMID 34590136 · DOI 10.1093/infdis/jiab387
Herpes Simplex Virus and Varicella Zoster Virus Infections in Cancer Patients.
Tayyar R, Ho D. · · 2023 · cited 47× · PMID 36851652 · DOI 10.3390/v15020439
Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond.
Weinberger B. · · 2021 · cited 31× · PMID 34627326 · DOI 10.1186/s12979-021-00249-6
Varicella Zoster Virus Infection: Clinical Features, Molecular Pathogenesis, Treatment, and Prevention.
Peng L, Song H, Li T, Ma Y, et al · · 2026 · PMID 41799932 · DOI 10.1002/mco2.70661

Verify or expand the search:

Other recruiting trials for Herpes Zoster

Currently open trials in the same condition.

NCT07400003 — Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine · Phase 1, PHASE2 · recruiting
NCT07307170 — The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster · NA · recruiting
NCT07293065 — A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell) · Phase 3 · active not recruiting
NCT07361796 — The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes · NA · recruiting
NCT07378046 — The Analgesic Efficacy and Safety of Baclofen in Patients With Herpes Zoster · NA · recruiting

Other Curevo Inc trials

Trials by the same sponsor.

NCT05304351 — Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03820414 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Curevo Inc
Last refreshed: 11 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03820414.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing